Mixed Phase 2b Results for Alumis Lupus Drug; Company Eyes Phase 3 in Subgroup
Alumis’ Phase 2b LUMUS trial of envudeucitinib missed overall SLE endpoints but showed robust responses in IFNGS-high patients. Psoriasis NDA still set for Q4 2026.
/ 4 items
#ALMS↓
Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
Alumis Psoriasis Drug Achieves 90% Skin Clearance in Phase 3 Trials
Alumis (ALMS) announces breakthrough Phase 3 results for envudeucitinib, a new oral medication for moderate-to-severe plaque psoriasis showing exceptional skin clearance rates.
Biotech Analyst Picks Signal Major Upside Into 2026
Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026.